CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Symbol: NASDAQ:CTSO
- CUSIP: N/A
- Web: www.cytosorbents.com
- Market Cap: $151.92 million
- Outstanding Shares: 28,133,000
- 50 Day Moving Avg: $5.14
- 200 Day Moving Avg: $4.78
- 52 Week Range: $3.30 - $6.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -15.88
- P/E Growth: 0.00
- Annual Revenue: $12.18 million
- Price / Sales: 12.47
- Book Value: $0.28 per share
- Price / Book: 19.29
- EBIDTA: ($10,410,000.00)
- Net Margins: -80.56%
- Return on Equity: -529.95%
- Return on Assets: -75.38%
- Debt-to-Equity Ratio: 1.00%
- Current Ratio: 3.17%
- Quick Ratio: 3.03%
- Average Volume: 120,120 shs.
- Beta: -0.56
- Short Ratio: 11.86
Frequently Asked Questions for Cytosorbents Corporation (NASDAQ:CTSO)
What is Cytosorbents Corporation's stock symbol?
Cytosorbents Corporation trades on the NASDAQ under the ticker symbol "CTSO."
How were Cytosorbents Corporation's earnings last quarter?
Cytosorbents Corporation (NASDAQ:CTSO) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The company had revenue of $3.57 million for the quarter, compared to analyst estimates of $3.29 million. Cytosorbents Corporation had a negative net margin of 80.56% and a negative return on equity of 529.95%. View Cytosorbents Corporation's Earnings History.
When will Cytosorbents Corporation make its next earnings announcement?
Where is Cytosorbents Corporation's stock going? Where will Cytosorbents Corporation's stock price be in 2017?
6 brokerages have issued 1-year target prices for Cytosorbents Corporation's stock. Their forecasts range from $7.00 to $24.00. On average, they expect Cytosorbents Corporation's stock price to reach $12.71 in the next twelve months. View Analyst Ratings for Cytosorbents Corporation.
What are analysts saying about Cytosorbents Corporation stock?
Here are some recent quotes from research analysts about Cytosorbents Corporation stock:
- 1. Maxim Group analysts commented, "Recall back in June of 2016 CytoSorbents entered into a Loan and Security Agreement with Western Alliance Bank, securing an initial $5 million, 4-year term loan with the option of another $5M. On June 30, 2017, the Company elected to drawdown the additional $5 million of funding available under the Loan and Security Agreement, bringing its total borrowings under the facility to $10 million." (7/5/2017)
- 2. HC Wainwright analysts commented, "CytoSorbents reported full-year 2016 financial results and held a conference call on March 3. The company reported revenues of $9.5M, higher than our estimate of $8.7M, and a net loss of $0.47 per share, compared to our estimated net loss of $0.40 per share. The differences mainly resulted from higher-than-expected product sales, offset by increased R&D and SG&A increases. We have updated our model to reflect the 2016 financial results." (3/6/2017)
Who are some of Cytosorbents Corporation's key competitors?
Some companies that are related to Cytosorbents Corporation include Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Neovasc (NVCN), Harvard Bioscience (HBIO), IRIDEX Corporation (IRIX), Viveve Medical (VIVE), EDAP TMS S.A. (EDAP), FULGENT GENETIC (FLGT), Presbia PLC (LENS), Digirad Corporation (DRAD), Electromed (ELMD), Luna Innovations Incorporated (LUNA), Invivo Therapeutics Holdings Corp (NVIV), Biolase (BIOL), EnteroMedics (ETRM), Advanced Oncotherapy PLC (AVO), Xtant Medical Holdings (XTNT) and Dextera Surgical (DXTR).
Who are Cytosorbents Corporation's key executives?
Cytosorbents Corporation's management team includes the folowing people:
- Al Kraus, Chairman of the Board
- Phillip P. Chan M.D., Ph.D., President, Chief Executive Officer, Director
- Kathleen P. Bloch CPA, Chief Financial Officer
- Vincent J. Capponi, Chief Operating Officer
- Eric G. Mortensen, Chief Medical Officer
- Michael G. Bator, Director
- James T. Gunton, Independent Director
- Edward R. Jones M.D., Independent Director
- Alan D. Sobel, Independent Director
Who owns Cytosorbents Corporation stock?
Cytosorbents Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Skylands Capital LLC (2.11%), Vanguard Group Inc. (1.61%), Advisor Group Inc. (0.19%), California Public Employees Retirement System (0.16%), PNC Financial Services Group Inc. (0.14%) and Northern Trust Corp (0.13%). Company insiders that own Cytosorbents Corporation stock include Al Kraus, Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents Corporation.
Who sold Cytosorbents Corporation stock? Who is selling Cytosorbents Corporation stock?
Who bought Cytosorbents Corporation stock? Who is buying Cytosorbents Corporation stock?
Cytosorbents Corporation's stock was bought by a variety of institutional investors in the last quarter, including Skylands Capital LLC and PNC Financial Services Group Inc.. Company insiders that have bought Cytosorbents Corporation stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents Corporation.
How do I buy Cytosorbents Corporation stock?
Shares of Cytosorbents Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytosorbents Corporation's stock price today?
MarketBeat Community Rating for Cytosorbents Corporation (NASDAQ CTSO)MarketBeat's community ratings are surveys of what our community members think about Cytosorbents Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cytosorbents Corporation stock can currently be purchased for approximately $5.40.
Earnings History for Cytosorbents Corporation (NASDAQ:CTSO)Earnings History by Quarter for Cytosorbents Corporation (NASDAQ CTSO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2017||Q2 2017||($0.06)||($0.04)||$3.29 million||$3.57 million||View||Listen|
|5/8/2017||Q1 2017||($0.11)||($0.05)||$2.99 million||$3.11 million||View||Listen|
|3/3/2017||Q4 2016||($0.10)||($0.16)||$2.59 million||$3.08 million||View||N/A|
|11/7/2016||Q3||($0.11)||($0.11)||$2.35 million||$2.14 million||View||Listen|
|8/9/2016||Q216||($0.09)||($0.12)||$2.18 million||$1.90 million||View||N/A|
|5/9/2016||Q116||($0.10)||($0.08)||$1.73 million||$1.80 million||View||N/A|
|3/9/2016||Q415||($0.08)||($0.08)||$1.51 million||$1.76 million||View||N/A|
|11/13/2015||Q315||($0.10)||($0.11)||$1.26 million||$1.30 million||View||Listen|
|8/13/2015||Q215||($0.11)||$0.05||$0.92 million||$0.96 million||View||Listen|
|5/11/2015||Q115||($0.13)||($0.11)||$0.80 million||$0.72 million||View||Listen|
|8/12/2014||Q2 2014||($0.01)||($0.01)||$1.13 million||$1.03 million||View||N/A|
Earnings Estimates for Cytosorbents Corporation (NASDAQ:CTSO)
2017 EPS Consensus Estimate: ($0.34)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cytosorbents Corporation (NASDAQ:CTSO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cytosorbents Corporation (NASDAQ:CTSO)
Insider Ownership Percentage: 5.60%Insider Trades by Quarter for Cytosorbents Corporation (NASDAQ:CTSO)
Institutional Ownership Percentage: 6.89%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/9/2017||Eric R Mortensen||Insider||Buy||2,500||$4.04||$10,100.00|| |
|6/9/2017||Michael G. Bator||Director||Buy||1,500||$4.12||$6,180.00|| |
|6/8/2017||Phillip P. Chan||Insider||Buy||3,700||$4.00||$14,800.00|| |
|6/8/2017||Vincent Capponi||COO||Buy||2,500||$4.00||$10,000.00|| |
|6/5/2017||Phillip P. Chan||Insider||Buy||6,300||$4.00||$25,200.00|| |
|5/15/2017||Kathleen P. Bloch||CFO||Buy||1,000||$4.34||$4,340.00|| |
|12/9/2016||Phillip P. Chan||Insider||Buy||4,600||$5.40||$24,840.00|| |
|12/6/2016||Kathleen P Bloch||CFO||Buy||1,000||$4.83||$4,830.00|| |
|8/24/2016||Phillip P Chan||Insider||Buy||5,000||$4.89||$24,450.00|| |
|6/7/2016||Michael G Bator||Director||Buy||3,000||$4.88||$14,640.00|| |
|10/29/2015||Vincent Capponi||COO||Sell||4,000||$7.50||$30,000.00|| |
|10/15/2015||Al Kraus||Director||Sell||6,774||$6.22||$42,134.28|| |
|10/8/2015||Al Kraus||Director||Sell||10,000||$6.39||$63,900.00|| |
|10/1/2015||Al Kraus||Director||Sell||10,000||$6.26||$62,600.00|| |
|9/24/2015||Al Kraus||Director||Sell||10,000||$6.44||$64,400.00|| |
|9/17/2015||Al Kraus||Director||Sell||10,000||$6.64||$66,400.00|| |
|9/10/2015||Al Kraus||Director||Sell||10,000||$7.26||$72,600.00|| |
|9/3/2015||Al Kraus||Director||Sell||10,000||$7.26||$72,600.00|| |
|8/27/2015||Al Kraus||Director||Sell||10,000||$6.39||$63,900.00|| |
|8/20/2015||Al Kraus||Director||Sell||10,000||$7.26||$72,600.00|| |
|8/13/2015||Al Kraus||Director||Sell||10,000||$6.26||$62,600.00|| |
|7/23/2015||Al Kraus||Director||Sell||10,000||$6.28||$62,800.00|| |
|7/16/2015||Al Kraus||Director||Sell||10,000||$6.33||$63,300.00|| |
|7/9/2015||Al Kraus||Director||Sell||10,000||$5.98||$59,800.00|| |
|7/2/2015||Al Kraus||Director||Sell||10,000||$6.29||$62,900.00|| |
|6/25/2015||Al Kraus||Director||Sell||13,205||$7.33||$96,792.65|| |
|6/18/2015||Al Kraus||Director||Sell||10,000||$5.78||$57,800.00|| |
|6/11/2015||Al Kraus||Director||Sell||10,000||$6.29||$62,900.00|| |
|6/4/2015||Al Kraus||Director||Sell||10,000||$6.30||$63,000.00|| |
|5/28/2015||Al Kraus||Director||Sell||10,000||$6.32||$63,200.00|| |
|11/17/2014||Al Kraus||Director||Sell||50,000||$0.23||$11,500.00|| |
|11/10/2014||Al Kraus||Director||Sell||50,000||$0.23||$11,500.00|| |
|11/3/2014||Al Kraus||Director||Sell||50,000||$0.23||$11,500.00|| |
|10/27/2014||Al Kraus||Director||Sell||100,000||$0.24||$24,000.00|| |
|10/10/2014||James T Gunton||Director||Sell||1,240,762||$0.24||$297,782.88|| |
|10/6/2014||Al Kraus||Director||Sell||50,000||$0.23||$11,500.00|| |
|9/29/2014||Al Kraus||Director||Sell||50,000||$0.23||$11,500.00|| |
|9/25/2014||Al Kraus||Director||Sell||41,500||$0.23||$9,545.00|| |
|9/22/2014||Al Kraus||Director||Sell||8,500||$0.23||$1,955.00|| |
|9/15/2014||Al Kraus||Director||Sell||50,000||$0.23||$11,500.00|| |
|9/12/2014||James T Gunton||Director||Sell||30,450||$0.24||$7,308.00|| |
|9/8/2014||Al Kraus||Director||Sell||50,000||$0.23||$11,500.00|| |
|9/5/2014||James T Gunton||Director||Sell||100,000||$0.24||$24,000.00|| |
|9/2/2014||Al Kraus||Director||Sell||50,000||$0.25||$12,500.00|| |
|9/2/2014||Kathleen P Bloch||CFO||Buy||65,000||$0.23||$14,950.00|| |
|8/28/2014||James T Gunton||Director||Sell||214,387||$0.24||$51,452.88|| |
|8/27/2014||James T Gunton||Director||Sell||1,360,000||$0.24||$326,400.00|| |
|8/25/2014||Al Kraus||Director||Sell||100,000||$0.25||$25,000.00|| |
|8/18/2014||Al Kraus||Director||Sell||100,000||$0.27||$27,000.00|| |
|8/11/2014||Al Kraus||Director||Sell||100,000||$0.28||$28,000.00|| |
|8/4/2014||Al Kraus||Director||Sell||50,000||$0.24||$12,000.00|| |
|7/21/2014||Al Kraus||Director||Sell||50,000||$0.24||$12,000.00|| |
|7/10/2014||Al Kraus||Director||Sell||50,000||$0.24||$12,000.00|| |
|7/7/2014||Al Kraus||Director||Sell||50,000||$0.24||$12,000.00|| |
|6/23/2014||Al Kraus||Director||Sell||50,000||$0.23||$11,500.00|| |
|6/18/2014||Al Kraus||Director||Sell||50,000||$0.24||$12,000.00|| |
|5/20/2014||Kathleen P Bloch||CFO||Buy||110,000||$0.24||$26,400.00|| |
|9/4/2012||Phillip P Chan||CEO||Buy||190,000||$0.13||$24,700.00|| |
Headline Trends for Cytosorbents Corporation (NASDAQ:CTSO)
Latest Headlines for Cytosorbents Corporation (NASDAQ:CTSO)
Cytosorbents Corporation (CTSO) Chart for Saturday, September, 23, 2017